 Double-blind Treatment Phase: Induction Melphalanprednisone and lenalidomide 10 mg MPR 2 treatment arms, or melphalanprednisone and placebo MPp 1 treatment arm for up to 9 cycles. If disease progression, subjects have the option to enter into the Open-Label Extension Phase. There is also an option to enter into the Follow-Up Phase. If the disease has not progressed, subject can continue on blinded therapy into Maintenance. 